FDA Allows Neuralink to Implant Brain Chip in Second Patient Following Fixes

Neuralink, the ambitious brain-computer interface company founded by billionaire Elon Musk, has been given the green light by the US Food and Drug Administration to implant its brain chip in a second human patient after addressing issues that arose in the first trial, as reported by the Wall Street Journal.

The initial problem of tiny wires inside the brain shifting out of position during the first implantation has been remedied by embedding the wires deeper into the brain, according to sources familiar with the company. This development comes after Neuralink’s groundbreaking achievement earlier this year when it successfully implanted a wireless brain chip in a human for the first time.

The company’s goal is to enable people to control computer devices using only their thoughts, a feat showcased by a paralyzed patient named Noland Arbaugh who played online chess using the Neuralink device to move the cursor on his laptop. While this technology holds great promise, the long-term success and safety of the brain chip implants remain to be seen.

Neuralink has been conducting human trials since receiving FDA approval in 2023, following years of research and testing on animals. Elon Musk, known for his innovation in the fields of technology and space exploration, has been vocal about the potential of Neuralink to revolutionize how humans interact with computers.

As the company continues to make strides in the field of neurotechnology, the world eagerly awaits to see how this cutting-edge technology will shape the future of human-machine interfaces.